Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Synlogic, Inc.
  6. Company
    SYBX   US87166L1008

SYNLOGIC, INC.

(SYBX)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo Synlogic, Inc.
Synlogic, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the drug discovery and development of Synthetic Biotic medicines. Its product pipeline includes Synthetic Biotic medicines for the treatment of metabolic disorders including Phenylketonuria (PKU) and Enteric Hyperoxaluria. The Company's lead product candidate includes SYNB1618, which is an oral therapy for the treatment of PKU. Its other product candidate SYNB8802 is developed for the treatment of Enteric Hyperoxaluria. The Company developed Synthetic Biotic medicines to treat certain cancers that are designed to modify the tumor microenvironment, activate the immune system and result in tumor reduction. It is developing SYNB1891 for the treatment solid tumors and lymphoma. The Company is conducting Phase II clinical trial with SYNB1618.

Number of employees : 72 people.
Sales per Business
20192020Delta
Synthetic Biology Therapeutics2.22100%0.55100% -75.49%
USD in Million
Sales per region
20192020Delta
United States2.22100%0.55100% -75.49%
USD in Million
Managers
Name Title Age Since
Aoife M. Brennan, Dr. President, Chief Executive Officer & Director 44 2019
Gregg D. Beloff Chief Financial Officer 52 2019
David L. Hava, Dr. Chief Scientific Officer 45 2020
Antoine Awad Chief Operating Officer 40 2020
Richard P. Shea Independent Director 68 2017
Peter Barrett, Dr. Chairman 67 2017
Nick Leschly Independent Director 47 2017
Edward T. Mathers Independent Director 60 2012
Patricia N. Hurter, Dr. Independent Director 56 2019
Michael M. Burgess, Dr. Independent Director 57 2020
Members of the board
Name Title Age Since
Peter Barrett, Dr. Chairman 67 2017
Richard P. Shea Independent Director 68 2017
Aoife M. Brennan, Dr. President, Chief Executive Officer & Director 44 2019
Nick Leschly Independent Director 47 2017
Edward T. Mathers Independent Director 60 2012
Patricia N. Hurter, Dr. Independent Director 56 2019
Michael M. Burgess, Dr. Independent Director 57 2020
Michael Thomas Heffernan Independent Director 55 2020
Lisa Kelly-Croswell Independent Director 53 2021
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 52,373,311 45,942,056 87.7% 0 0.0% 87.7%
Shareholders
NameEquities%
Fidelity Management & Research Co. LLC 7,855,233 11.7%
RA Capital Management LP 6,666,666 9.89%
Ginkgo Bioworks Holdings, Inc. 6,340,771 9.41%
OrbiMed Advisors Private Equity 6,029,995 8.95%
NEA Management Co. LLC 4,229,410 6.28%
Atlas Venture, Inc. 2,651,963 3.94%
The Vanguard Group, Inc. 1,701,998 2.53%
Gilder, Gagnon, Howe & Co. LLC 1,317,925 1.96%
Aquilo Capital Management LLC 1,043,922 1.55%
Dimensional Fund Advisors LP 952,835 1.41%
Company contact information
Synlogic, Inc.
301 Binney Street
Suite 402
Cambridge, MA 02142

Phone : +1.617.401.9975
Web : http://www.synlogictx.com
Brand Portfolio
In partnership withAllbrands.markets
More brands of Synlogic, Inc.